Patents by Inventor Kuno WUERSCH

Kuno WUERSCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF
    Publication number: 20240252668
    Abstract: This application discloses microorganisms and methods of producing GNAQ/GNA11 inhibitors and methods of making antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The disclosure also relates to formulations comprising antibody drug conjugates of anti-PMEL 17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA1 inhibitor and methods of treating or preventing cancer using the formulations.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 1, 2024
    Inventors: Liqiong Fan, Dominik Hainzl, Roee Ramot, Shwetha Iyer, Joseph Anthony D'Alessio, Kuno Wuersch, Dominik Pistorius, Eusebio Manchado Robles, Kathrin Buntin, Doris Gabriel, Boris Fessler, Pierre Maudens, Vincent Romanet, Anne-Sophie Bluemmel, Keith Hoffmaster, Eshita Khera, Padmaja Yerramilli-Rao
  • Combinations of FGFR4 inhibitors and bile acid sequestrants
    Patent number: 11229643
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: January 25, 2022
    Assignee: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Diana Graus Porta, Jacqueline Kinyamu-Akunda, Andreas Joerg Mahl, Luigi Manenti, Andreas Weiss, Armin Wolf, Kuno Wuersch
  • COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS
    Publication number: 20200261444
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Application
    Filed: November 1, 2017
    Publication date: August 20, 2020
    Applicant: NOVARTIS AG
    Inventors: Robin Alec FAIRHURST, Diana GRAUS PORTA, Jacqueline KINYAMU-AKUNDA, Andreas Joerg MAHL, Luigi MANENTI, Andreas WEISS, Armin WOLF, Kuno WUERSCH